(精选)【医学英文课件】 Le strategie terapeutiche a progressione dopo gli Inibitori di EGFR di Ia e IIa generazione.教学课件.pptVIP

Lucio Buffoni ONCOLOGIA POLMONARE AZIENDA OSPEDALIERO-UNIVERSITARIA SAN LUIGI GONZAGA DI ORBASSANO;Background;Kind of Progressions: not all progressions are made equal!!!;Different Progression - Different behaviour;Different Progression - Different behaviour;Different Progression - Different behaviour; Primary endpoint: PFS1 (time to RECIST PD or death);La prosecuzione di erlotinib post-PD aumenta il PFS;LUX Lung 1 – Afatinib vs Placebo;Janjigian ESMO 2012;Horizontal pathway: EGFR inhibition + bypass signaling JO25567: bevacizumab + erlotinib first-line;ACCRU: bevacizumab + erlotinib fir